Perrin White, MD

Perrin White, MD


Chief, Division of Pediatric Endocrinology
Audre Newman Rapoport Distinguished Chair in Pediatric Endocrinology
UT Southwestern Medical Center
Dallas, TX

Related Videos

Knowing the genetic underpinnings of the disease, how does this impact our current approach to CAH and suggest novel approaches for targeting specific pathways that drive the hypothalamic-pituitary-axis in CAH? Video

Knowing the genetic underpinnings of the disease, how does this impact our current approach to CAH and suggest novel approaches for targeting specific pathways that drive the hypothalamic-pituitary-axis in CAH?

Although the CAHtalyst trials establish that you can improve 17-hydroxprogesterone and androstenedione levels while lowering the glucocorticoid dose, can we predict long-term benefits? Video

Although the CAHtalyst trials establish that you can improve 17-hydroxprogesterone and androstenedione levels while lowering the glucocorticoid dose, can we predict long-term benefits?

How do we identify patients in late adolescence who might benefit from reductions in steroid dose? And who might be ideal candidates for CRF antagonists such as crinecerfont? Video

How do we identify patients in late adolescence who might benefit from reductions in steroid dose? And who might be ideal candidates for CRF antagonists such as crinecerfont?

Once the diagnosis of 21-OH deficiency CAH has been established, what are the current therapeutic approaches at different times of life and, by extension, what are the unmet therapeutic needs? Video

Once the diagnosis of 21-OH deficiency CAH has been established, what are the current therapeutic approaches at different times of life and, by extension, what are the unmet therapeutic needs?

What should we look to in the future as far as our improved understanding of where and how CRF antagonists will fit into the therapeutic landscape for CAH? Video

What should we look to in the future as far as our improved understanding of where and how CRF antagonists will fit into the therapeutic landscape for CAH?

How do the clinical end points and therapeutic concerns change as persons with CAH become adolescents and mature into early adulthood? Video

How do the clinical end points and therapeutic concerns change as persons with CAH become adolescents and mature into early adulthood?

Although you have emphasized the current role of corticosteroid therapy in CAH, are there other adjunctive treatments that also play a role? Video

Although you have emphasized the current role of corticosteroid therapy in CAH, are there other adjunctive treatments that also play a role?

What strategies are used to compensate for glucocorticoid-mediated side effects? Video

What strategies are used to compensate for glucocorticoid-mediated side effects?

Can you tell us a bit about the history of CAH—how it was discovered and what has shaped your lifelong interest in this condition, especially in the pediatric population? Video

Can you tell us a bit about the history of CAH—how it was discovered and what has shaped your lifelong interest in this condition, especially in the pediatric population?